BE in hepatic impairment? [BE/BA News]

posted by nobody – 2019-08-30 09:29 (702 d 13:30 ago) – Posting: # 20530
Views: 1,228

Hello again!

Today I have to read this here:

But the originator found differences in PK in mild/moderate hepatic impairment not worth any dose adjustment according to the current label and the differences as outlined in the FDA AssRep are unimpressive. I'm trying to figure out a formulation-related influence of hepatic function on BA/BE...

Lawyers looking for some work? How low can you go? Is that state-of-the-art in 2019?

Kindest regards, nobody

Complete thread:

 Admin contact
21,596 posts in 4,516 threads, 1,532 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Sunday 22:59 CEST (Europe/Vienna)

Sit down before fact as a little child,
be prepared to give up every conceived notion,
follow humbly wherever and whatever abysses nature leads,
or you will learn nothing.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz